VanEck Vectors Morningstar Durable Dividend ETF DURA 深 沪
等待开盘 06-25 09:30:00 美东时间
37.4725
-0.152
-0.40%
华盛通- 最 高37.56
- 今 开37.56
- 成交量 503股
- 最 低 37.4725
- 昨 收 37.6243
- 总市值 3747.25万
- 52周最高 38.6952
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 30.6359
- 委 比 8.05%
- 总股本 100.00万
- 历史最高 38.6952
- 量 比 0.26
- 振 幅 0.23%
- 历史最低 13.3187
- 每 手 1
- 风险率 2.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts As Board Director
BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of
05-28 19:49
BrainStorm Cell Therapeutics appoints former FDA official Peter Pitts to board
BrainStorm Cell Therapeutics appoints former FDA official Peter Pitts to board BrainStorm Cell Therapeutics appointed former FDA Associate Commissioner Peter J. Pitts to its board, effective immediately. Pitts is president and co-founder of the Center for Medicine in the Public Interest. The appoint
05-28 19:46
BRIEF-Hapag-Lloyd CEO At AGM Duration And Impact Of The Middle East Conflict On Freight Rates, Demand And Costs Remain Uncertain
BRIEF-Hapag-Lloyd CEO At AGM Duration And Impact Of The Middle East Conflict On Freight Rates, Demand And Costs Remain Uncertain May 20 (Reuters) - Hapag-Lloyd AG HLAG.DE : HAPAG-LLOYD CEO AT AGM: DURATION AND IMPACT OF THE MIDDLE EAST CONFLICT ON FREIGHT RATES, DEMAND AND COSTS REMAIN UNCERTAIN Fu
05-20 17:23
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
Eyepoint Pharma (($EYPT)) has held its Q1 earnings call. Read on for the main h...
05-20 11:18
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
Eyepoint Pharma (($EYPT)) has held its Q1 earnings call. Read on for the main h...
05-08 10:20
NPK International Q1 2026 Earnings Call: Complete Transcript
NPK International (NYSE:NPKI) released first-quarter financial results and host...
05-01 21:58
Medtronic enrolls first patient in ENDURANCE study of Altaviva tibial neuromodulation device
Medtronic enrolls first patient in ENDURANCE study of Altaviva tibial neuromodulation device Medtronic enrolled first patient in ENDURANCE post-approval study of Altaviva implantable tibial neuromodulation device for urge urinary incontinence. Clinical results have not been presented; study will tra
04-29 22:47
BRIEF-AOTI Reports Study In 3,126 Patients Shows Superior Durable Healing With TWO2 Therapy
BRIEF-AOTI Reports Study In 3,126 Patients Shows Superior Durable Healing With TWO2 Therapy April 27 (Reuters) - Aoti Inc AOTI.L : AOTI INC - STUDY IN 3,126 PATIENTS SHOWS SUPERIOR DURABLE HEALING WITH TWO2 THERAPY AOTI INC - STUDY SHOWS 64.8% COMPLETE HEALING RATE, 2.7% RECURRENCE IN CHRONIC LOWER
04-27 14:22
BRIEF-ISS Extends, Expands Contract With Fulham Road Collaborative
BRIEF-ISS Extends, Expands Contract With Fulham Road Collaborative April 27 (Reuters) - Iss A/S ISS.CO : EXTENDS AND EXPANDS CONTRACT WITH THE FULHAM ROAD COLLABORATIVE IN THE UK CONTRACT HAS DURATION OF FIVE YEARS, WITH OPTION TO EXTEND FOR FURTHER FIVE YEARS Source text: ID:nGNX8l997v Further comp
04-27 13:02
Endurance Technologies Strengthens Board and Senior Management Bench
Endurance Technologies Ltd. ( ($IN:ENDURANCE) ) has issued an update. Endurance...
04-16 22:31
